Davies D, Larbi K, Allen A, Sanz M, Weg V B, Haskard D O, Lobb R R, Nourshargh S
Applied Pharmacology, Imperial College School of Medicine at the National Heart & Lung Institute, London, UK.
Immunology. 1999 May;97(1):150-8. doi: 10.1046/j.1365-2567.1999.00766.x.
The aim of the present study was to investigate the role of the adhesion pathway alpha4 integrins/vascular cell adhesion molecule type 1 (VCAM-1) in rapid eosinophil accumulation induced by the chemoattractants PAF and LTB4. For this purpose we have used an in vivo model of local 111In-eosinophil accumulation to quantify eosinophil accumulation induced by intradermal administration of platelet-activating factor (PAF) and leukotriene B4 (LTB4) in rats. Initial experiments carried out over 4 hr demonstrated that intravenous administration of an anti-VCAM-1 monoclonal antibody (mAb; 5F10) or an anti-alpha4 integrin mAb (TA2) caused a significant reduction in PAF- or LTB4-induced 111In-labelled eosinophil accumulation. Time-course experiments demonstrated that the anti-VCAM-1 mAb was effective at suppressing early phases of the 111In-labelled eosinophil accumulation induced by PAF and LTB4 (e.g. within the first 60 min). In contrast, 111In-labelled eosinophil accumulation induced by these chemoattractants was unaffected by the local administration of the transcriptional inhibitor actinomycin D, suggesting a role for basally expressed VCAM-1. Indeed, basal expression of VCAM-1 in rat skin sites was demonstrated by the localization of intravenously administered radiolabelled mAb. The localization of the radiolabelled antibody was not altered in skin sites injected with PAF or LTB4. Finally, the inhibitory effects seen with the anti-VCAM-1 mAb were enhanced when the antibody was co-injected into rats with an anti-intercellular adhesion molecule-1 (ICAM-1) mAb (1A29). The combination of these two mAb also caused a significant inhibition of PAF-induced oedema, as quantified by the local accumulation of 125I-labelled human serum albumin. The results indicate a role for alpha4 integrins/VCAM-1 and ICAM-1, in PAF- and LTB4-induced eosinophil accumulation in vivo and suggest that basally expressed VCAM-1 may have a functional role in rapid accumulation of eosinophils induced by chemoattractants.
本研究的目的是探讨黏附途径α4整合素/血管细胞黏附分子1(VCAM-1)在趋化因子血小板活化因子(PAF)和白三烯B4(LTB4)诱导的嗜酸性粒细胞快速积聚中的作用。为此,我们使用了局部111铟-嗜酸性粒细胞积聚的体内模型,以量化大鼠皮内注射血小板活化因子(PAF)和白三烯B4(LTB4)诱导的嗜酸性粒细胞积聚。最初在4小时内进行的实验表明,静脉注射抗VCAM-1单克隆抗体(mAb;5F10)或抗α4整合素mAb(TA2)可显著减少PAF或LTB4诱导的111铟标记的嗜酸性粒细胞积聚。时间进程实验表明,抗VCAM-1 mAb在抑制PAF和LTB4诱导的111铟标记的嗜酸性粒细胞积聚的早期阶段(例如在最初60分钟内)有效。相反,这些趋化因子诱导的111铟标记的嗜酸性粒细胞积聚不受转录抑制剂放线菌素D局部给药的影响,这表明基础表达的VCAM-1起了作用。实际上,静脉注射放射性标记的mAb的定位证明了大鼠皮肤部位VCAM-1的基础表达。在注射PAF或LTB4的皮肤部位,放射性标记抗体的定位没有改变。最后,当抗VCAM-1 mAb与抗细胞间黏附分子-1(ICAM-1)mAb(1A29)共同注射到大鼠体内时,观察到的抑制作用增强。这两种mAb的组合也显著抑制了PAF诱导的水肿,这通过125碘标记的人血清白蛋白的局部积聚来量化。结果表明α4整合素/VCAM-1和ICAM-1在体内PAF和LTB4诱导的嗜酸性粒细胞积聚中起作用,并表明基础表达的VCAM-1可能在趋化因子诱导的嗜酸性粒细胞快速积聚中具有功能作用。